Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Walter Yip"'
Autor:
Caroline A. Lohrisch, Nathalie LeVasseur, S Baxter, Walter Yip, Caroline Illmann, K Dobosz, Christine E. Simmons, Kaylie-Anne Willemsma
Publikováno v:
Current Oncology
Volume 27
Issue 2
Pages 5635-92
Curr Oncol
Volume 27
Issue 2
Pages 5635-92
Curr Oncol
The use of Oncotype dx (Genomic Health, Redwood City, CA, U.S.A.) testing has been shown to change treatment decisions in approximately 30% of breast cancer (bca) cases, but research on how Recurrence Score testing has affected the type of chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e05d1abbb7d3207733fa8ee75a6251da
https://doi.org/10.3747/co.27.5635
https://doi.org/10.3747/co.27.5635
Autor:
Walter Yip, Huaqi Li, Kaylie-Anne Willemsma, Nathalie LeVasseur, Christine Simmons, Caroline F. Illmann, Lovedeep Gondara, Stephen Chia
Publikováno v:
Clinical breast cancer. 19(6)
Although neoadjuvant chemotherapy (NACT) has been established as a standard for medically fit patients with locally advanced breast cancer, there has been renewed interest in utilizing neoadjuvant endocrine therapy (NET) for women with estrogen recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2354baa283e5598067a47984b83e89f1
https://pubmed.ncbi.nlm.nih.gov/31279611
https://pubmed.ncbi.nlm.nih.gov/31279611
Publikováno v:
Journal of Clinical Oncology. 35:e12049-e12049
e12049 Background: The Oncotype DX test has been shown to change treatment plans in ~30% of cases, but it is unclear if it changes the type of chemotherapy offered. We sought to determine if the availability of Oncotype DX testing in BC resulted in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b25868d2469dd1f97f7307f97c004045
https://doi.org/10.1200/jco.2017.35.15_suppl.e12049
https://doi.org/10.1200/jco.2017.35.15_suppl.e12049
Autor:
Kaylie Willems, Miranda Mcdermott, Caroline Illmann, Christine E. Simmons, Walter Yip, Huaqi Li, Nathalie LeVasseur
Publikováno v:
Journal of Clinical Oncology. 35:581-581
581 Background: While neoadjuvant chemotherapy (NACT) has been established as the standard of care for medically fit patients, there has been renewed interest in utilizing neoadjuvant endocrine therapy (NET) for the treatment of women with estrogen-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6667c9f9fec248786bb34dcd8ac6308d
https://doi.org/10.1200/jco.2017.35.15_suppl.581
https://doi.org/10.1200/jco.2017.35.15_suppl.581